Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
111 hedge funds and large institutions have $255M invested in Concert Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 15 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 40
8% less funds holding
Funds holding: 120 → 111 (-9)
12% less capital invested
Capital invested by funds: $290M → $255M (-$35M)
43% less call options, than puts
Call options by funds: $331K | Put options by funds: $583K
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$8.89M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.98M |
| 3 |
Renaissance Technologies
New York
|
+$1.95M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.44M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Matarin Capital Management
New York
|
-$5.33M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$3.54M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$3.07M |
| 4 |
Millennium Management
New York
|
-$1.87M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.28M |
CNCE Hedge Fund Activity: Q3 2018 in Review
111 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2018, worth a combined $255M — down 12% from $290M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CNCE and 7 opened new positions — a net loss of 8 holders — while 40 trimmed existing stakes and 42 added.
The largest buyer was First Manhattan, opening a new position worth an estimated $8.89M. The largest seller was Matarin Capital Management, exiting entirely with an estimated $5.33M sold.
- 111 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2018, down from 120 in Q2 2018.
- Funds reported $255M of Concert Pharmaceuticals, Inc. stock for Q3 2018, down 12% quarter-over-quarter.
- 7 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2018 and 15 closed out, a net change of -8 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2018 was First Manhattan, an estimated $8.89M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2018 was Matarin Capital Management, an estimated $5.33M sold.
Based on aggregated 13F filings for Q3 2018.